Press releases
Maximuscle powers Vodafone McLaren Mercedes drivers through the 2012 Formula 1™ season
Leading sports nutrition brand continues its presence with on-car logos in Hungary
Once-daily dolutegravir is non-inferior to twice-daily raltegravir in treatment-naïve adults with HIV-1
Shionogi-ViiV Healthcare LLC present full 48-week data results from SPRING-2 Phase III study at International AIDS Conference
Results announcement for the second quarter 2012
GSK delivers Q2 core EPS of 26.4p and dividend of 17p
GSK pre-broadcast statement on BBC Panorama: “The truth about Sports Products”, 19 July 2012
GlaxoSmithKline today issued the following statement in anticipation of the BBC Panorama programme, “The truth about sports products”, which is scheduled to be aired this evening.
GlaxoSmithKline and Amicus Therapeutics expand Fabry disease collaboration
Glaxo Group Limited (GSK) and Amicus Therapeutics (Nasdaq: FOLD) today announced an expansion of their collaboration to develop and commercialise the investigational pharmacological chaperone migalastat HCl for Fabry disease.
GlaxoSmithKline celebrates its role in supporting the biggest anti-doping operation in the history of the Olympic Games
GSK today marks its role as Official Laboratory Services Provider for the London 2012 Olympic and Paralympic Games by launching its first UK advertising campaign to celebrate the role that anti-doping science will play in helping ensure this summer’s Games are the cleanest possible.
GSK to acquire Human Genome Sciences for US$14.25 per share in cash
GlaxoSmithKline plc (LSE: GSK) and Human Genome Sciences (NASDAQ: HGSI) today announced that the companies have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash.
GSK and Theravance announce regulatory submissions for FF/VI in the US and Europe
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of regulatory applications in the US and European Union for the once-daily investigational medicine fluticasone furoate “FF”/vilanterol “VI” (FF/VI) for patients with chronic obstructive pulmonary disease (COPD) and a regulatory application for asthma in the European Union.
US Regulatory Update – Tykerb® (lapatinib)
GSK plc announced today that it has withdrawn a supplemental NDA to the US FDA for Tykerb (lapatinib) in combination with trastuzumab for the treatment of patients with HER2 (ErbB2)-positive metastatic breast cancer who have received prior trastuzumab therapy.
GSK announces positive data from Harmony 8 and completion of clinical registration package for albiglutide in type 2 diabetes
GSK today announced that data have been received from the Phase III Harmony 8 study and from the event driven meta-analysis for assessment of cardiovascular safety conducted across the albiglutide clinical programme.
